Selecting the right ex vivo hematologic model is crucial in cancer drug development. These models offer a cost-effective and efficient platform for screening drug candidates, enabling researchers to prioritize the most promising candidates before advancing to in vivo testing. 👉Read our latest blog to learn the key factors to consider when using ex vivo hematologic oncology models in your research and dive deeper into hematologic malignancies and discover how ex vivo models help predict drug responses across diverse patient cohorts. 🔗Read the blog here : https://hubs.li/Q03dVmnB0 🔬Also explore how Champions' premier hematologic malignancy ex vivo screen can transform your research: https://hubs.li/Q03dVwLg0 #CancerResearch #DrugDevelopment #ExVivoModels #Oncology #PreclinicalTesting #DrugScreening #CancerTherapy immunotherapy #exvivo #bloodcancer
Champions Oncology, Inc.
Biotechnology
Hackensack, New Jersey 10,008 followers
US-based, End-to-End Oncology Pharmacology Solutions CRO
About us
Champions Oncology, Inc. provides an end-to-end range of research and development solutions and services that improve the productivity of oncology drug development. Using both in vitro to in vivo testing platforms companies can leverage the expertise at Champions Oncology to help guide decision making for clinical development scenarios. From screens using commercially-available and custom cell lines, to studies leveraging syngeneic or traditional patient-derived studies xenograft (PDX) models, and modeling treatment response in the clinic, Champions Oncology is your partner in meeting today’s needs and innovating for tomorrow’s challenges. At the core of our services is the Champions TumorGraft® (CTG) platform, a comprehensive, unique compendium of PDX models that preserve the biological characteristics of human tumors and are highly predictive of clinical outcomes. Services utilizing Champions TumorGrafts® PDX tumor models include evaluating tumor sensitivity/resistance to various single, combination, standard and novel chemotherapy agents, biomarker discovery and the identification of novel drug combinations. Champions TumorGraft® PDX models are procured through agreements our Clinical Collaboration Network, a series of renowned oncology institutions in the US and around the world, as well as through the company’s Personalized Oncology Solutions business. Personalized Oncology Solutions assist clinical oncologists by establishing and administering expert tumor panels for their patients to analyze medical records and test results, to assist in understanding conventional and experimental options and to identify and arrange for testing, analysis and study of the patients’ cancer tissues, as appropriate. Additionally, the company offers personalized PDX development, drug studies and genome sequencing, whereby physicians evaluate the effects of cancer drugs and understand the genetic makeup of each patient’s tumor, enabling them to better select treatment regimens.
- Website
-
http://www.championsoncology.com
External link for Champions Oncology, Inc.
- Industry
- Biotechnology
- Company size
- 201-500 employees
- Headquarters
- Hackensack, New Jersey
- Type
- Public Company
- Founded
- 2007
- Specialties
- Translational Oncology Research, Personalized Oncology, Patient Derived Xenograft, Oncology Pharmacology, Immuno-Oncology, Flow Cytometry, Syngeneic Models, Humanized Mouse Models, Clinical Flow Cytometry, PDX, 3D Organoid Models, Clinical Specialty Testing, Hematological Modeling, Leukemia Models, GCLP, Cancer Vaccine Research, Preclinical Oncology Research, Global Clinical Trials, Ex Vivo Platforms, CDX, Cell Line Screening, Organoid Screening, Orthotopic Modeling, Computational Biology, Bioinformatics, Proteomics, and Multi-Omics
Locations
-
Primary
Get directions
Hackensack
Hackensack, New Jersey 07601, US
-
Get directions
1330 Piccard Dr
Suite 025 & 104
Rockville, Maryland 20850, US
-
Get directions
Via L. Ariosto 21, 1st Floor
Bresso MI, 20091, IT
-
Get directions
4 Oppenheimer St., Ha’ogen Building B
Rehovot, 7670104, IL
Employees at Champions Oncology, Inc.
Updates
-
💡Will you be attending the Bio-IT World Conference & Expo in Boston, MA, from April 2-4, 2025? 🌟 Join our team, Matt Newman, Gervaise Henry, Carrie Weston, at the annual conference and discuss Champions' revolutionary data platform that leverages the power of Champions' proprietary PDX model curated multi-modal data, computational science, and bioinformatics. 💬 Book a meeting today: https://hubs.li/Q03dBvYX0 #BioITWorld2025 #OncologyData #ComputationalScience #DrugDiscovery #Bioinformatics #cancerresearch
-
-
🚀 We’re live at IO360! Meet our experts Mara Gilardi PhD, mMBA, Nathalie Leger, and Chelsea Riveley, MBA at booth #11 to learn more about our ex vivo & in vivo platforms for preclinical cancer drug development and our fully compliant clinical specialty testing services to support successful cancer clinical trials. Let’s connect and discuss how we can advance your cancer research! Book a meeting now: https://hubs.li/Q03d959M0 #IO360 #ClinicalResearch #DrugDevelopment #PreclinicalResearch #ImmunoOncology #Immunotherapy #Oncology #CancerResearch
-
-
Flow cytometry-based receptor occupancy (RO) assays are essential for optimizing antibody-based treatments. By providing key pharmacokinetic (PK) and pharmacodynamic (PD) insights, these assays help refine dosing strategies and improve therapeutic outcomes. 🔬 Key RO Assays: ✅ Total receptor levels – Assess target expression and minimize off-target effects. ✅ Free receptor levels – Support PK/PD modeling and dose optimization. ✅ Drug-occupied receptors – Alternative measurement when free receptor assays aren't feasible. Integrating RO assays into preclinical and clinical development can drive smarter, more effective treatment strategies. 📖 Read our blog to learn more: https://hubs.li/Q03c-5Fz0 #ReceptorOccupancy #FlowCytometry #DrugDevelopment
-
Champions is excited to meet you at AACR 2025 in Chicago! Join us at Booth #839 to explore how our innovative platforms and preclinical and clinical testing services are driving next-generation of cancer drug development research. Discover the future of oncology with us! Our team is unveiling 16 cutting-edge research posters that highlight how our unique PDX bank and extensive multi-omics dataset are revolutionizing cancer research. Each novel poster features in vivo, ex vivo, or clinical specialty testing platforms that support our biopharma partners in accelerating target discovery to clinical success. 📍Check out each upcoming AACR poster and add the session to your calendar here: https://hubs.li/Q03cs3d_0 We look forward to connecting with you at AACR 2025! #AACR2025 #OncologyInnovation #CancerBreakthroughs #cancerresearch #cancertherapy #immunooncology
-
📅 Join Champions' expert team at BVS' Waltham/Winter Street Biotech Expo this Thursday, March 20th! Meet with Nathalie Leger and Chelsea Riveley to discuss how our innovative services and revolutionary platforms can transform your preclinical programs and clinical trials. Register for free here: https://lnkd.in/g-GGaaXb #BVSExpo #oncology #OncologyResearch #preclinicalresearch #clinicalspecialtytesting #flowcytometry #PDXmodels #Organoids
-
-
🚨 Final Call! Enrollment Closes March 31, 2025! 🚨 Enrollment for Champions Oncology’s 10 Model SynScreen ends March 31, 2025—don’t miss your chance to leverage the industry's most advanced syngeneic screening platform! Featuring 10 robust murine models, this platform delivers highly predictive data on immunotherapies efficacy and mechanisms by testing it in a fully immune-competent murine system. Enroll Today: https://hubs.li/Q03cfy9x0 #cancer #cancertherapy #immunooncology #immunotherapeutics #immunotherapy #syngeneicmousemodels #oncology #preclinical #translationalresearch #IO
-
-
Passionate about making a difference in the fight against cancer? Join the Champions Oncology team of scientific innovators! Explore our open positions and apply today! https://hubs.li/Q03bQs1F0 #Hiring #Jobs #CancerResearch #OncologyResearch #careers
-
-
Thank you for making our Annual European Translational Oncology Symposium a success! We were honored to host many passionate scientists and industry professionals dedicated to advancing IO and oncology drug development in Basel, Switzerland. 🎉From thought-provoking presentations to valuable networking opportunities, it was amazing to see new ideas and collaborations take shape. A special thank you to our expert speakers Enzo Medico, MD, PhD, Sara Colombetti, PhD, Serena Bologna, PhD, Diana Gomes, PharmD, PhD, Michael R., PhD, MBA, and Stefano Cairo, PhD, your insights made this event unforgettable. 🎉To everyone who attended: THANK YOU for making this symposium such a success. We look forward to continuing these conversations and seeing you at future events! #Networking #CancerResearch #IO #TranslationalOncology #ChampionsOncology #OncologyInnovation #CancerResearch #TranslationalOncology2025 #CancerTherapies #ImmunoOncology #PreclinicalResearch #OncologySymposium #RAS #KRAS #ProteinKinases #LipidKinases
-
-
🚨 Now Enrolling: Systemic AML In Vivo Screen – Until May 15th, 2025! 🚨 Champion’s Systemic Acute-Myeloid Leukemia AML In Vivo Screen features 27 rare, patient-derived AML models, meticulously characterized to retain key AML-specific molecular characteristics and mutations. These extensively characterized models provide a clinically relevant platform to evaluate therapeutic efficacy, with several models pretreated using advanced therapies like FLT3 inhibitors, anti-CD33 ADCs, and stem cell transplants—helping researchers accelerate the next generation of AML therapeutics. 📅 Secure your spot today. Let’s accelerate AML breakthroughs together: https://hubs.li/Q03b26jG0 #AMLResearch #Hematology #DrugDiscovery #OncologyResearch #PreclinicalModels #DrugDevelopment #PreclinicalStudies #AcuteMyeloidLeukemia #invivo #bloodcancers
-